Type 2 diabetes may reduce life expectancy and patients' quality of life due to its micro-and macro-vascular complications and to the higher risk of several types of cancer. An emerging important factor is represented by the hepatic involvement; it is recognized that excessive hepatic fat accumulation represents a typical feature of diabetic patients and that it also plays an important pathogenic role. It is now evident that non-alcoholic fatty liver disease (NAFLD), generally perceived as a benign condition, may have on the contrary an important deleterious impact for diabetic patients increasing the risk to develop cardiovascular complications but also serious hepatic diseases, in particular non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Lifestyle intervention, bariatric surgery and several drug therapies have now accumulated evidence of efficacy in treating NASH. On the other hand, their durability and safety in the long-term is yet to be proven and their use may be sometimes associated with side effects or higher risk of adverse events limiting the regular administration or contraindicating it. Professional health care providers, building awareness about the importance of these hepatic complications, should put more efforts in primary prevention using a behavioral therapy needing a multidisciplinary approach, in secondary prevention applying on a regular basis in the clinical setting available predictive algorithms to identify the patients at higher cardiovascular and hepatologic risk, and in tertiary prevention treating, when not contraindicated, the diabetic patients preferentially with drugs with proven benefit on NAFLD/NASH.
Type 2 diabetes and hepatic diseases
Reduced life expectancy in patients with type 2 diabetes (T2DM) is associated with large prevalence of atherosclerosis and cardiovascular diseases, chronic kidney disease and cancer, but also to a wide spectrum of chronic hepatic diseases ultimately able to lead to hepatic cirrhosis and hepatocellular carcinoma (HCC) [1, 2] . In patients with hepatic cirrhosis a high prevalence of diabetes has been recognized since 1906 when the term "hepatogenous diabetes" was first reported [3] . In fact, patients with hepatic cirrhosis are known to be characterized by profound alterations of insulinmediated glucose metabolism [4] leading to impaired glucose tolerance in 60-80% and overt diabetes in 10-20% of the patients [5] [6] [7] . At the same time, patients with T2DM may be characterized by a wide spectrum of hepatic disease going from the simple abnormality of the circulating levels of hepatic enzymes to cirrhosis, HCC and liver failure and also HCV-related hepatic disease and cholelitiasis are more frequent in diabetic than in non-diabetic individuals.
Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic liver disease and it is largely prevalent in patients with T2DM. NAFLD is defined as the presence of hepatic steatosis (> 5% of hepatocytes by histology or > 5.6% by Magnetic Resonance Spectroscopy; MRS), no significant alcohol consumption (< 21 drinks/week for men; < 14 drinks/week for women) and no competing etiologies for hepatic steatosis [8, 9] . Many authors consider NAFLD as a relevant pathogenic risk factor for diabetes due to the fact that affected patients show the same quantitative and qualitative pattern of multi-organ insulin resistance not only with respect to glucose but also fatty acids and amino acids metabolism of overt T2DM [10] .
Based on these epidemiologic and pathophysiologic observations it may be concluded that a reciprocal association exists between T2DM and NAFLD, with diabetes negatively influencing the severity and prognosis of NAFLD, and NAFLD increasing the risk to develop diabetes and its cardiovascular and renal complications in the future. This vicious cycle makes the diabetic patient with chronic hepatic disease a formidable challenge for many professional health care providers in their clinical settings.
Influence of NAFLD on T2DM

Experimental evidence
Impact on insulin resistance
The large amount of data generated in the last 10-15 years by noninvasive measurements of intrahepatic lipid content using ultrasound (semi-quantitative) and 1 H MRS (quantitative) allowed the recognition that NAFLD is associated with several insulin-dependent metabolic impairments: suppression of hepatic glucose production, stimulation of muscle glucose disposal, suppression of adipose tissue lipolysis [10] regardless of the presence of diabetes [11, 12] , even if some other metabolic aspects remain controversial [13] . Interventional studies demonstrated a direct link between insulin resistance and NAFLD [14] . In diabetic patients a low-calorie, low fat diet is associated with an 81% reduction of hepatic triglyceride content with a proportional improvement of hepatic insulin sensitivity [14] ; hepatic fat content rather than other metabolic parameters is associated with insulin requirements in T2DM patients when insulin therapy is indicated [15] . In addition, there are numerous correlative reports suggesting a primacy of liver fat content over other anthropometric and metabolic parameters in influencing whole body insulin sensitivity [16, 17] . In both non-diabetic and T2DM patients the liver fat content is associated with insulin resistance more tightly than the intra-myocellular lipid content, the visceral fat content, the deep abdominal subcutaneous fat content [18] . In metabolically healthy obese subjects, insulin sensitivity is strongly associated with a low intrahepatic triglyceride content more than with other anthropometric or metabolic parameter [19] . Similarly, we found that in obese adolescents with hepatic steatosis whole body insulin resistance and impaired glucose tolerance are more severe when compared with obese adolescents with comparable body fat, but normal intrahepatic triglyceride content [20] . In disorders characterized by loss of adipose tissue (as in congenital lipodystrophies), insulin resistance is associated with massive hepatic steatosis and chronic leptin treatment improves insulin-stimulated hepatic and peripheral glucose metabolism in parallel with a considerable reduction in hepatic and muscle triglyceride content [21] .
Impact on β-cell function
It is important to emphasize that if excessive fat accumulation within hepatocytes is well established to be associated with insulin resistance, the association between hepatic steatosis and pancreatic β-cell function remains unclear. Intrahepatic triglyceride content is positively associated not only with fasting plasma insulin, but also with fasting plasma c-peptide, a more robust measure of β-cell secretion [22] ; in particular we reported that non-diabetic individuals with fatty liver are characterized not only by insulin resistance but also by enhanced fasting pancreatic β-cell function, regardless of the anthropometric features typical of patients with fatty liver as confirmed also by others [23] . These data would suggest that not only insulin resistance but probably also hyperinsulinemia at the portal site is an important factor for the genesis of hepatic steatosis and insulin resistance at the peripheral sites [24, 25] ; in fact, hyperinsulinemia caused by an impaired insulin hepatic clearance could implicate a peripheral insulin resistance (in muscle and adipose tissue) as demonstrated in subjects with an hyperinsulinemia caused by an insulinoma [26] . In support of this hypothesis, Petrides et al. observed that a continuous infusion of Octreotide is able to induce reduction of hyperinsulinemia and a normalization of insulin sensitivity in cirrhotic insulinresistant patients [27] .
Impact on systemic low-grade inflammation
The activation of inflammatory pathways in the liver shares with the adipose tissue remarkably similar mechanisms. In fact, genes involved in fatty acid partitioning and binding, lipolysis, and monocyte/macrophage recruitment and inflammation are overexpressed in biopsy of human fatty liver of T2DM subjects [28] . In both tissues, elevated circulating FFA concentrations may be responsible for triggering this response [29] eventually leading to the intra-cellular activation of NF-кB-related inflammatory pathways as supported by studies in animal models [30] .
Epidemiological evidence
Prospective studies found that high activities of ALT and γGT predict the development of T2DM [31, 32] . ALT predicts the development of T2DM independently of classical diabetes risk factors and c-reactive protein [33] and a largescale population analysis showed that ALT levels slightly just over the limit of normal values are correlated with an increased risk to develop diabetes [34] .
Few studies examined the association between morphological markers (ultrasound-detected) of fatty liver and T2DM. In a cohort of Korean people, fatty liver on ultrasonography was associated with the development of T2DM [35] and similar findings were reported in a case-control Chinese [36] and Japanese [37] studies.
There is a large discussion about the use of surrogate markers of NAFLD, simply to be used in epidemiological research and to be potentially validated from a clinical standpoint; Bedogni et al. proposed the "fatty liver index" (FLI) [38] (based on BMI, waist circumference, triglycerides and GGT) and Balkau et al. proposed the "NAFLD fatty liver score" [39] and both scores were predictive of incident diabetes.
Influence of NAFLD on micro-vascular complications
It was recently suggested that NAFLD may represent and independent risk factor for the renal disease in patients with diabetes [40] . There are several observational studies supporting this hypothesis and a comprehensive meta-analysis of 33 cross-sectional and prospective studies (including a total of nearly 64,000 individuals) confirmed that the presence and severity of NAFLD, as diagnosed by biochemistry, imaging or histology, was associated with a nearly twofold increase in the prevalence and incidence of CKD [41] . Although the results of this meta-analysis provide robust evidence of this association it is important to emphasize that causality remains to be proven.
Some evidence of association between NAFLD and peripheral neuropathy in patients with type 1 diabetes [42] and retinopathy in a pediatric cohort of non-diabetic individuals [43] were reported but they need a more robust set of data to establish also in this case a direct causal relationship.
Influence of NAFLD on cardiovascular disease
Accumulating evidence suggests that cardiovascular disease dictates the outcome of patients with NAFLD more frequently and to a greater extent than does the progression of liver disease [44, 45] .
Endothelial dysfunction
The endothelial dysfunction represents a typical feature of the very early stages of the atherosclerotic disease and the vasodilatory response, mediated by nitric oxide released by the endothelial epithelium, in vivo, represents its classical biomarker which can be easily and noninvasively quantified in response to the shear stress generated by artery occlusion mediated by a sphygmomanometer cuff. Villanova et al.
[46] evaluated the flow-mediated vasodilation of the brachial artery in patients with NAFLD reporting a reduced response compared with controls. This defect was more pronounced in the subgroup of patients with steatohepatitis (NASH) in comparison to those with simple fatty liver.
Coronary dysfunction
There are not conclusive data about the coronary dysfunction severity in patients with NAFLD. In fact, Lautamaki et al.
[47] studied 55 T2DM patients with coronary artery disease using positron emission tomography (PET) techniques and segregated them in two subgroups with low and high liver fat content, respectively. Using this approach the authors could not demonstrate the presence of a severe coronary dysfunction in patients with NAFLD in comparison to those without. Assy et al. [48] analyzed 29 patients with fatty liver and 32 sex-and age-matched individuals without NAFLD as controls using imaging techniques. When compared with controls, NAFLD patients showed a higher prevalence of calcified and noncalcified coronary plaques and higher prevalence of non-obstructive coronary stenosis. Fatty liver (assessed by computed tomography, CT) proved to be a strong predictor of coronary syndrome independent of indicators for metabolic syndrome and inflammation (C-reactive protein levels).
Cardiac energy metabolism
In the above mentioned study by Lautamaki et al. [47] , the use of PET in combination with the administration of 2-deoxy-2-[
18 F]fluoro-d-glucose and 15 O-labeled water, quantified simultaneously cardiac insulin sensitivity and blood flow in patients with T2DM and coronary artery disease and found that myocardial insulin resistance was more severe in the subgroup of diabetic patients with NAFLD than in those without it. Another study, performed using 31 P-MRS, reported that in the resting state the left ventricular high-energy phosphates metabolism of individuals with recent diagnosis of fatty liver is impaired when compared with individuals carefully matched for anthropometric features and with a normal liver fat content [49] .
Cardiac function
There are mounting evidences that NAFLD may be independently associated with early alteration of cardiac function. Initial data reported left ventricular diastolic dysfunction in patients with type 2 [50] and NAFLD when compared to control diabetic patients without NAFLD. In a more robust fashion, in this direction a recent study in which liver ultrasonography and trans-thoracic echocardiography (with speckle-tracking strain analysis) was performed in 222 diabetic patients in primary cardiovascular prevention showed that NAFLD was independently associated with a three-fold increased odds of mild and/or moderate severity of left ventricular diastolic dysfunction graded according to the current criteria of the American Society of Echocardiography [51] .
Cardiac arrhythmias
Community-based studies reported that moderately elevated GGT levels [52] and transaminases [53] were independently associated with an increased incidence of atrial fibrillation further supporting the initial observation by Targher et al. showing that increased GGT levels and hepatic steatosis was associated with increased incidence of atrial fibrillation [54] and had additive and independent effects on the prevalence of permanent/persistent atrial fibrillation in a hospital-based sample of patients with type 2 diabetes [55]. More recently the same authors reported that in the same hospital setting NAFLD is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus [56] .
Heart valve disease
It is known that the process of calcification of the aortic and mitral valves is associated with established risk factors for atherosclerosis, and following this line of thinking there are data showing that NAFLD is an independent predictor of cardiac calcification in both the aortic and mitral valves in patients with type 2 diabetes [57].
Epidemiological evidence
As for the association with the onset of T2DM, several studies used GGT as a marker of NAFLD and The British Regional Heart Study is likely the largest available in the literature. This is a prospective study of 6997 men aged 40-59 with no history of CVD (CHD or stroke) or diabetes drawn from general practitioner in 24 British towns and followed up for 24 years. In this cohort, elevated GGT was associated with significantly increased risk of stroke, fatal CHD events and CVD mortality independent of established CVD risk factors (Framingham score) [58] . Studies in which NAFLD was detected based on abdominal ultrasonography, are fewer. In a prospective observational study with a total of 1637 apparently healthy Japanese subjects the incidence of cardiovascular disease (coronary heart disease, ischemic stroke, and cerebral hemorrhage) was higher in subjects with NAFLD at baseline than in subjects without NAFLD independently to conventional risk factors during 5 years of follow-up [59] . Also in the Verona Study, during 5 years of follow-up, in a cohort of 248 T2DM patients and 496 controls, who were free of diagnosed CVD at baseline, subjects with NAFLD subsequently developed nonfatal coronary heart disease (myocardial infarction and coronary revascularization procedures), ischemic stroke, or cardiovascular death more frequently than subjects without NAFLD [60] . The Valpolicella Heart Study [61] and the Study of Health in Pomerania [62] reported similar results using again the abdominal ultrasonography. We also tested the hypothesis using the above mentioned FLI (fatty liver index) within the 15-year general population Cremona study, demonstrating that this surrogate biomarker of fatty liver was independently associated with hepatic-related deaths (hepatic cirrhosis and HCC) but also with all-cause, CVD, and cancer mortality rates [63] . FLI correlated also with the homeostasis model assessment of insulin resistance (HOMA-IR), but when HOMA-IR was included in the multivariate analyses, FLI retained its association with hepatic-related mortality but not with all-cause, CVD, and cancer-related mortality, suggesting from a statistical but not necessarily biological standpoint a primacy of the systemic insulin-resistant state over the fatty liver, as major mediator of the prognostic history. Under this view a balanced analysis should take into consideration also contradictory findings in the literature. In the Diabetes Heart Study, 623 participants were evaluated for hepatic steatosis, defined as a liver:spleen attenuation ratio of < 1.0 by computed tomography (CT). In this study visceral fat, subcutaneous fat, coronary, aortic, and carotid artery calcium were also simultaneously assessed by CT and carotid atherosclerosis by ultrasound. The analysis of the data did not confirm an association between the estimated fatty liver content and coronary, aortic, carotid calcium, or carotid intimal thickness [64] . In the Dijon study, 101 patients with T2DM were studied using 1 H-MRS to determine liver fat and ultrasonography to measure carotid intima-media thickness (IMT); fatty liver was not a determinant factor associated with carotid intima-media thickness [65] . The results of this study are in contrast with those of a similar study by Targher et al. [66] in which patients with biopsy-proven NAFLD had a markedly greater carotid IMT than control subjects and carotid IMT was greater in NASH compared with a simple fatty liver disease.
Influence of T2DM on NAFLD
Obesity and diabetes represent important risk factors affecting consistently the prognosis of patients with NAFLD not only because of cardiovascular complications but also for hepatologic complications.
Pathogenic mechanisms
The liver damage in patients affected by NAFLD was historically explained by a set of events described as "twohits hypothesis" [67] . According to this vision, the first insult would be represented by the accumulation of triglycerides within hepatocytes, eventually mediating systemic insulin resistance, and the second insult represented by the oxidative stress resulting from the dysfunctional oxidative energy metabolism at mitochondrial level generating free radicals and lipid peroxidation products. This sequence of events would determine membrane damage, and in turn hepatocyte apoptosis, triggering of the local inflammatory process. Recently, more complex models, named "multiple parallel hits", have been proposed [68] ; this hypothesis emphasizes the role of multiple and different processes able to contribute to the development of a liver inflammation in which the role of intestinal microbiota and its products, the adipose tissue and venular stasis play a novel and important role.
The two most relevant hepatologic complications in patients with NAFLD are cirrhosis and HCC. With respect to the first issue, patients with diabetes are often overweight/obese, and the unbalanced, excessive or reduced production of adipokines released by the adipose tissue (leptin and adiponectin, respectively, represent the paradigmatic players in this view), may be involved in increased fibrogenic activity, inflammatory processes, endoplasmic reticulum stress and apoptosis which may be further worsened by an iron overload [69, 70] . Further, even if most of the HCC cases appears as a consequence of hepatitis B/C virus infections, in approximately 50% of cases it is hypothesized at least an indirect role of obesity and T2DM, as a consequence of the action facilitating the evolution into NASH [71] . The above described pro-fibrogenic factors and insulin resistance in particular may also mediate a pro-carcinogenic effect; phosphatidylinositol 3-kinase (PI3K)/phosphatase and the PTEN/ Akt axis can be influenced by this altered system with a disequilibrium facilitating the cellular and tissue growth, apoptosis, survival and differentiation. In particular, PTEN, a tumor suppressor is usually mis-regulated in conditions such as obesity, insulin resistance, and T2DM, and could represent the metabolic pathway involved in the HCC pathogenesis [72] . In a therapeutic perspective this may be a relevant issue because all strategies focused on substituting the β-cell function and potentially generating hyperinsulinemia (sulfonylureas and insulin) seems to be associated with a worse prognosis when compared, in observational studies, with insulin sensitizing approaches [73, 74] .
Epidemiological evidence
Cirrhosis
It is recognized for many years that among American people with NAFLD, diabetes, and even earlier dysglycemia conditions such as the intolerance to oral glucose challenge (oral glucose tolerance test, OGTT), or obesity, increase the risk of a progression to fibrosis and an augmented hepatology mortality [75] . Additionally, data related to the Italian population would suggest the same especially within the first year following the onset of diabetes. In these population studies the adverse prognostic impact of diabetes seems to be even more important than the presence of cirrhosis at baseline [76, 77] and cryptogenic cirrhosis, typically associated with diabetes, represented the third condition for indication to liver transplantation in the United States [78] .
HCC and cholangiocarcinoma
Some epidemiologic data would support the association between diabetes and the risk of HCC and cholangiocarcinoma [79] [80] [81] even if it remains to be clarified the sequence of events in the natural history of these patients. In particular according to some authors, HCC development in diabetic patients could manifest itself also in absence of a previous transition in fibrosis/cirrhosis [82, 83] .
HCV infection
It is well known that the prevalence of HCV infection is higher in patients with diabetes in comparison to the normal population; prevalence of antibodies against HCV is 4.2% in diabetic patients and 1.6% in the general population [84, 85] . A simple explanation is that a specific effect of HCV infection increases the predisposition to develop diabetes with respect to patients with HBV infection (20 vs. 10%) [85] . In particular HCV seems to be able to interfere with the insulin receptor substrate signaling [86] and it is also known that among the possible HCV genotypes, genotype 3 could be the most important one, presumably for its capability to induce insulin resistance [87] in association with high TNF-α levels and low adiponectin levels, that makes patients particularly predisposed to the development of liver steatosis. It is also important not to forget the possible interaction between the HCV infection and its pharmacological treatment (Interferon in the past) and the onset of diabetes.
Acute liver failure
The incidence of hepatic insufficiency is higher in patients with diabetes than the general population (2.31 vs. 1.44 per 1000 persons/year) [88] . The pharmacological therapy used 1 3 in diabetes plays a fundamental role in this association [89] taking into account it cannot be exclusively limited to the potential hepatic toxicity of anti-diabetic drugs but also to all the other drugs typically used in patients with diabetes [90] .
Treatment options of NAFLD/NASH
Patients with T2DM are therefore a subgroup of individuals in which the presence of NAFLD may be an important independent risk factor in terms of both cardiovascular and hepatologic complications and at this stage of our knowledge the question whether NAFLD should be actively treated to prevent these complications needs an answer urgently. To this end the ideal therapy for patients with NAFLD/NASH should achieve three goals: (1) decreasing disease activity, (2) delaying progression of fibrosis, (3) reducing CVD risk factors. The reduction of the CVD risk factors may be maximized with their control focused in carefully obtaining required targets for glycemic (hemoglobin A1c), lipid (LDL-and non-HDL-cholesterol) and blood pressure [91] following the related guidelines based on the cardiovascular disease risk assessment.
Methodological issues in NASH-related RCTs
Whether a drug with specific effectiveness in decreasing the activity of NAFLD and reducing fibrosis is available at this stage remains matter of considerable interest. Several treatments have shown evidence of efficacy in RCTs of varying design. In spite of this and regardless the substantial population burden of disease, especially in patients with T2DM, there are no approved treatments for NAFLD/NASH and the reason is because published trials are often too divergent to allow meaningful comparisons. For this reason a methodological consensus on key end-points and clinical trial design for NASH has been established by the American Association for Study of Liver Diseases on the conception, design, execution, key end-points and interpretation of the interventional RCTs [92] . The Food and Drug Administration (FDA) recognizes NASH as a clinical indication for treatment, but not NAFLD [93] . As a consequence the aim (and related end-point) for an interventional RCTs is to demonstrate that the treatment must (1) induce at least a two-point improvement in the NAFLD Activity Score (NAS) and (2) produce no disease progression (no worsening in fibrosis/cirrhosis). NAS was developed to provide a numerical score for patients who most likely have NASH [94] . NAS is the sum of the separate scores for steatosis, hepatocellular ballooning, lobular inflammation (Table 1) even if it cannot be used as a surrogate of histological diagnosis of NASH which is based on evaluation of other pathologic patterns. It is important to recall that NAS does not predict liver-related morbidity or mortality, whereas the presence of NASH is associated with worse liver-related outcomes and all-cause mortality. Mild intra-acinar and mild portal Score 3
Severe intra-acinar and mild portal (2) No progression of liver fibrosis
Lifestyle intervention: first-line therapy for NAFLD/ NASH
Weight loss
Weight loss is the best predictor of reductions in liver fat and aminotransferases [95] . The amount of weight lost is a determinant of histologic improvements in liver injury and fibrosis, the larger the reduction (≥ 10%), the better the histologic improvement [96] and a noninvasive prediction model including weight loss, T2DM, alanine aminotransferase normalization, age, and NAS may be used to identify NASH resolution in patients under lifestyle intervention [97] . The nutritional intervention needs to be focused on restricting the calorie intake and even if the Mediterranean diet showed a beneficial role in mortality from all causes, cardiovascular disease, cancer, obesity and T2DM [98] dietary macronutrient manipulation seems to be less efficient than caloric restriction [99] in NAFLD.
Physical exercise
The efficacy of exercise for the reduction of liver fat is recognized and recommended. Level of physical activity is associated with intrahepatic fat content [100] . Interventional studies showed that the reduction of liver fat by aerobic exercise regimens occurred without clinically significant weight loss and no difference in efficacy was found by either aerobic exercise dose or intensity [101] , therefore, the optimal 'type' of exercise and whether resistance training is also as efficacious in reducing hepatic fat as aerobic exercise is unknown. The level of current evidence would suggest that resistance training should complement, rather than replace, aerobic exercise training [102] in accordance with the clinical recommendation for prevention and treatment of T2DM.
Results of the available interventional RCTs
Thiazolidinediones (TZDs)
The most promising results generated by RCTs for the treatment of NASH were generated with Pioglitazone. The first report performed in 101 patients with impaired glucose tolerance (IGT) or overt diabetes randomized in a double blind placebo-controlled fashion to treatment with Pioglitazone 30-45 mg/die on top at the nutritional regimen for 6 months showed a reduction of the intrahepatic fat content, of the inflammation, ballooning and necrosis and a trend for reduction of fibrosis [103] . Recently the follow-up of this study showed that following an 18 months observational period the treatment was associated with the achievement of the above described FDA-suggested primary end-point (2-point improvement in NAS no worsening in fibrosis) in 29/58 (58%) in Pioglitazone vs. 9/17 (17%) in placebo (p < 0.001) in parallel with the improvement of liver fat content, histological markers of hepatocellular damage, and score of fibrosis [104] . These findings confirm, with a markedly more robust and convincing set of results, previous studies generated in the past with Pioglitazone in non-diabetic subjects [105, 106] and less convincingly with Rosiglitazone which showed a robust effect only in reducing liver fat content.
Vitamin E
Oxidative stress, as well insulin resistance, is an attractive target for therapy in patients with NAFLD. The rationale on testing vitamins with potential anti-oxidant effects has its basis on the fact that it prevents liver injury by blocking intrinsic apoptotic pathways and by protecting against mitochondrial toxicity. It was for this reason that The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), decided to test the hypothesis in the Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis (PIVENS) trial, a phase 3, multicenter, randomized, placebo-controlled, double blind clinical trial [106] . In this RCTs more than 180 non-diabetic patients were allocated to receive treatment with Pioglitazone (30 mg/die), vitamin E (800 UI die) or placebo for 96 weeks. Both Pioglitazone, as anticipated above and vitamin E achieved the primary end-point and also the FDA-recommended end-point of improving NAS without any effect on fibrosis. However, there are some concerns that long-term use of vitamin E may be associated with increased all-cause mortality, increased incidence of hemorrhagic stroke.
Obeticholic acid
Lipophilic bile acids may be potent modulators of insulin sensitivity decreasing hepatic gluconeogenesis and circulating triglycerides [107] . These effects are believed to be mediated by decreased hepatic lipid synthesis and enhanced peripheral clearance of VLDL [108, 109] . Since the bile acid derivative 6-ethylchenodeoxycholic acid (Obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that was shown to reduce liver fat and fibrosis in animal models of NAFLD [110] , the RCTs FLINT was designed to test this hypothesis in humans. Sixty non-diabetic patients were randomized to receive Obeticholic acid or placebo in a double blind placebo-controlled fashion for 72 weeks [111] . The FDA-suggested primary end-point (2-point improvement in NAS no worsening in fibrosis) could be detected in 50/110 (45%) in treatment vs. 23/109 (21%) in placebo (p < 0.0002); in parallel Obeticholic acid improved hepatic steatosis, inflammation, hepatocyte ballooning, and fibrosis.
Obeticholic acid might therefore represents a useful therapeutic option in patients with NAFLD even if emerging more recent data of its effects on insulin resistance are more controversial than previously thought and the lipid profile may be adversely affected by this agent. In addition, pruritus is frequently observed during treatment and might lead to treatment discontinuation.
Glucagon-like peptide-1 receptor agonists (GLP1-RA)
GLP1-RAs hold a compelling rationale for testing the hypothesis that this gut-derived incretin hormone, inducing weight loss and improving insulin sensitivity might have beneficial effects in NAFLD. GLP-1-RA showed to reduce liver enzymes and oxidative stress as well as improve liver histology in animal models of NAFLD with indirect or direct effects decreasing de-novo lipogenesis and increasing fatty acid oxidation [112, 113] . The LEAN study recently published by Armstrong et al. [114] is the first-in-class, RCT in patients with NAFLD. Liraglutide 1.8 mg die administered for 48 weeks met the primary end-point of histological resolution of NASH with no worsening in fibrosis. In addition to improvements in histological steatosis and hepatocyte ballooning, fewer patients receiving Liraglutide had progression of fibrosis than in the placebo group. Although patients in the Liraglutide group met the primary end-point, Liraglutide did not result in significant mean changes in the composite NAS, as reported with Pioglitazone, vitamin E, and Obeticholic acid.
Bariatric surgery
Lifestyle intervention is first-line therapeutic tool for NAFLD, but in the large majority of obese patients it produces only modest weight loss. In severely or morbidly obese patients (BMI > 40 or BMI 35-40 kg/m 2 with comorbidities), bariatric surgery induces long-term maintenance of weight loss and whatever the surgical procedure, a 14-25% weight loss is observed up to 10 years after surgery, along with improvement in insulin resistance, remission of diabetes and fewer cardiovascular events [115] . In support of a potential role of bariatric surgery as a therapeutic option in morbidly and/or complicated obese patients, the data generated from a prospective non-controlled study including 109 patients with biopsy-proven NASH who underwent bariatric surgery (biliointestinal by pass, laparoscopic adjustable gastric band (LAGB), Roux-en-Y gastric bypass, sleeve gastrectomy at Lille Bariatric Cohort, France) from May 1994 through May 2013 showed that comparing biological, and histologic data before and 1 year after surgery NASH disappeared in nearly 85% of the patients [116] allowing the authors to conclude that in this group of patients not responding to lifestyle intervention, bariatric surgery should be taken into consideration.
Elafibranor
Elafibranor is an agonist of the PPAR-α and PPAR-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation and demonstrated efficacy in disease models of NAFLD/NASH and liver fibrosis [117] . A recent RCT performed in patients with NASH without cirrhosis randomly assigned to receive Elafibranor 80 mg (n = 93), Elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks showed that in intention-to-treat analysis, there was no significant difference between the Elafibranor and placebo groups in the protocol-defined primary outcome (reversal of NASH without worsening of fibrosis). However, NASH resolved without fibrosis worsening in a higher proportion of patients in the 120-mg Elafibranor group vs the placebo group (19 vs 12%; OR 2.31; 95% CI 1.02-5.24; p = 0.045), based on a post hoc analysis for the modified definition. Elafibranor did produce a mild, reversible increase in serum creatinine [118] .
Yet to come RCTs and therapies under development
Traditional lifestyle intervention and endoscopic bariatric procedures are promising although more randomized trials are needed. The long-term safety of several available drugs that demonstrated efficacy for the treatment of NASH remains to be established (Table 2 ). There are some uncertainty about the long-term safety of vitamin E. Pioglitazone is associated with osteopenia, fluid retention and weight gain. Obeticholic acid causes pruritus in a substantial proportion of subjects and Elafibranor has been associated with transient rises in creatinine. Several exciting therapies are under development and results of clinical and post-marketing trials will help elucidate their safety.
An ongoing phase III study examines the long-term effects of Obeticholic acid treatment in patients with NASH and fibrosis on both histology and overall mortality (REGENERATE Trial). In the meantime, LJN452, another potent oral FXR agonist which is structurally not related to bile acids is currently in phase II development for NASH patients (FLIGHT-FXR).
An ongoing phase III study (RESOLVE-IT) investigates the effects of Elafibranor 120-mg treatment for 72 weeks on the reversal of NASH without worsening of fibrosis and a composite end-point of overall mortality, cirrhosis, and liver-related complications after 4 years. As another candidate IVA337, a pan-PPAR agonist which activates three different receptor isoforms α, δ, and γ, has shown a beneficial safety profile in clinical phase I.
A different mode of action to be tested is the simultaneous anti-inflammatory and antifibrotic effect with substances that are in the clinical development program. Cenicriviroc is a dual inhibitor of the chemokine receptors CCR2 and CCR5 with fast track status by the FDA. In a recent placebocontrolled, randomized phase II study in NASH patients with liver fibrosis cenicriviroc (150 mg) has been tested for a treatment duration of 12-24 months (CENTAUR trial). After 12 months of treatment, significantly more patients in the cenicriviroc reached the defined primary end-point with improvement in fibrosis without worsening of NASH whereas NASH reversal (complete resolution) was not different (AASLD Liver Meeting, Boston 2016, Abstract LB-1).
The ASK1 inhibitor (apoptosis signal-regulating kinase 1, selonsertib) represents another substance with beneficial effects on inflammation, apoptosis, and fibrosis. Recent phase II study data in NASH patients documented a significant reduction of fibrosis without worsening of NASH (no difference in NAS reduction by > 2 or diagnosis resolution) with a considerably short treatment duration of only 24 weeks selonsertib compared to placebo (AASLD Liver Meeting, Boston 2016, Abstract LB-3).
Pegylated FGF21 (BMS-986036) represents a substance derived from the FGF family. FGF21 plays a central role in glucose and lipid metabolism and in a phase I study in healthy obese subjects this compound demonstrated a beneficial effect on body weight, insulin resistance, serum triglycerides, and LDL-cholesterol and a recent phase II study in T2DM patients showed a significant improvement in insulin sensitivity (composite insulin sensitivity index) and serum lipid profiles (AASLD Liver Meeting, Boston 2016, Abstract 17A-33). A phase II study in NASH patients is ongoing.
SGLT2-inhibitors
Drugs in this class documented beneficial effect for the treatment of NAFLD in animal models and more recently short term treatment with Ipragliflozin showed similar effects on hepatic fat content when compared to Pioglitazone [119] and Luseogliflozin was shown to be superior to metformin [120] , both studies performed in Japanese patients with T2DM. Appropriate RCTs with validate NASH-related end-points will be necessary to establish a beneficial effect of SGLT2-inhibitors in patients.
Open question and take home messages
The most difficult question to answer is what will be the target population of future NAFLD/NASH treatment. Should we treat all diabetic patients with a fatty liver? This would represent the majority of people with T2DM. Treating an early stage of simple steatosis in diabetic patients, based on the above described hepatologic risk of people with diabetes, is an attractive option to prevent a future progress toward NASH. However, in diabetic patients it will be difficult to achieve. A more practicable strategy could be to treat individuals progressing toward fibrosis; these progressing patients need to be identified using recommended screening algorithms. Following this line of reasoning identification of meaningful biomarkers to predict disease progression, liverrelated events, and overall mortality are urgently needed, and additional research is necessary in this field because it is known that among T2DM patients with normal plasma aminotransferase levels, the prevalence of NAFLD is as high as 50 and 56% of these patients have histologic confirmation of NASH [121] . Unfortunately, histological findings remain the only tool to have diagnosis in these patients and stadiation of the severity of the disease; for this reason screening procedure with biomarkers easy to be applied in the clinical setting are eagerly awaited.
As professional health care providers we should perform primary prevention of NAFLD based on multidisciplinary health education programs [122] focused on body weight reduction and lifestyle modification; at this stage this remains the most important tool. In secondary prevention, the available established screening algorithms should be applied on a regular basis to identify patients at higher risk. In tertiary prevention patients with NAFLD/NASH may take advantage of the fact that they could be preferentially treated, when not contraindicated, with drugs with proven benefit on the liver disease.
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